11 Jan 2019 Governance
Leukaemia UK and Leuka have merged
We are delighted to announce that on 1 November Leuka and Leukaemia UK merged, bringing together two of the UK’s leading leukaemia and blood cancer charities to create one charity dedicated to innovative research and care for people affected by blood cancers. The two charities have joined forces under the name Leukaemia UK, uniting Leuka’s 37 years’ experience in ground-breaking medical research with Leukaemia UK’s four decades of pioneering care.
From research to care, the new charity will continue to put people affected by blood cancers at its heart. Together, Leukaemia UK aims to carry out even more world-class research and advances in care.
Leukaemia UK will be led jointly by Leuka’s CEO Olive Boles and Leukaemia UK’s CEO Angela Smith-Morgan. The charity’s new Chair of Trustees is Chris Corbin, current Chair of Leuka, who is supported by a Board including both Leuka and Leukaemia UK Trustees.
Related posts
2 October 2023
Three leading charities collaborate to fight childhood cancers
New Partnership we3can to fund research into three most common childhood cancers Today (2nd October 2023), three leading cancer charities have launched a new collaboration in order to improve the…
7 November 2022
Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives
Ian McCafferty CBE will take up the role in January 2023, from current Chair of Trustees, Chris Corbin OBE, and will lead the charity as it continues to grow. Chris…
12 June 2021
First Medical Research Council and Leukaemia UK Clinical Research Training Fellow shares project highlights
Dr Sandeep Potluri’s findings will contribute towards a better understanding, cure and treatments of leukaemia and blood cancers
12 December 2022
Widespread coverage of new leukaemia therapy shows promise in first trial patient
As you may have seen in the news over the weekend, a clinical trial investigating a new leukaemia treatment has shown promising results. As part of the trial, funded by…